Moleculera Labs is committed to providing research-backed, clinical testing services that support physicians in recognizing, and more accurately diagnosing Neuropsychiatric Disorders. Through our ongoing research and development we anticipate discovering additional testing markers that will help doctors more readily diagnose the many individuals suffering from treatable autoimmune Neuropsychiatric Disorders.
My son was diagnosed after many weeks of not knowing what was wrong. He is 16! He has had the Cunningham Panel run. I appreciate your work. Without your research my son would not have recovered.
I want to thank your company for making this test available. We thought we had "lost" our Sarah. The report really shows what is wrong with her. Now the doctors will know how to further treat her, we will forever be indebted to your lab for this amazing work you are doing for all the PANDAS/ PANS children.
Christina Lau-Raman, Sarah's mother
i am so thankful to have the Cunningham Panel to confirm the PANDAS diagnosis for my daughter, who is now 18 and who exhibited PANDAS symptoms as early as age 7, without a diagnosis until one year ago. We are still working on the right treatment and getting her to accept the diagnosis so she will take her medication. Our daughter has almost all the classic symptoms, but your nurse hit the nail on the head when she pointed out one of the markers where my daughter scored very high, and that can manifest as anger - that is the first thing we notice when she begins to flare, and no one else has ever made this connection. We are so appreciative to have quantifiable results because we previously second-guessed ourselves so many times, and now we know it's not just our imagination, bad parenting or some kind of hidden psychiatric illness. Thank you so much for giving us hope!
Martha Shoultz Arroyo
My 17 year old daughter had been suffering for several years with all kinds of neurological and psychiatric issues. By the time we got to a PANS specialist who finally ordered the test her findings were extreme and it was the confirmation and proof we needed that my daughter was suffering from a treatable autoimmune disorder. It was worth every penny and I’m so thankful that this test was available to us! After two IVIG treatments and appropriate treatment under a PANDAS/PANS specialist she is almost 80 percent recovered.
The Cunningham Panel saved the lives of our two children who had life-threatening autoimmune encephalomyelitis. Our son's test came back at 4/5, and our daughter's 5/5. From there, we were able to get treatments: plasmapheresis and IVIG for both kids; Rituximab additionally for our daughter. My husband and I had the privilege of running into Dr. Cunningham on an elevator at a conference, and we expressed to her how grateful we are for her extremely hard work in caring for these kids. We told her she helped save our kids' lives. She was so humble and kind - she was just so happy to hear how well they were doing. Thank you to Dr. Cunningham and Moleculera Labs. You are truly the best.
We would not be here today receiving treatment instead of cross admonitions to use a stronger hand to control the child, we would not be here today getting infusion treatment except for the work of Moleculera. Please tell your investors. Your staff and your trusting investors are affecting the lives of real people.
We ordered the Cunningham Panel as a complementary diagnostic tool to be used in conjunction with other tests to aid in and confirm our physician's clinical diagnosis of PANDAS for our daughter. The results of the Cunningham Panel took 3 months to receive and our daughter had already received her first IVIG. Our insurance plan would not cover the cost of the IVIG. To our delight and surprise our daughter's physician called us to inform us that not only had our insurance company authorized coverage of the initial IVIG but pre-authorized a second IVIG based on the Cunningham Panel results.
Carmel, St. Louis
I wanted to take this opportunity to thank all of you at Moleculera Labs for helping me and my son with his Cunningham Panel. Your customer service is by far the best in the nation and you all put parents like me at so much ease and comfort. Thank you for understanding that our kids have special needs and still how important they are to us. Thank you for making a difference in the lives of our children by just doing what you love to do. Thank you for giving parents like me a direction to move forward. I am so grateful to Moleculera's nurse for taking the time to go over the results with me and explaining it so well. You all are a blessing to parents like us from the point you pick up the phone until the parent has reached the comfort level of the results.
God Bless Each and Every one of you.
Ananda, North Carolina
My name is Wendy Elliott, I am Adam Elliott's mother. A little history, my husband and I have been searching for answers to some of Adam's behavioral issues since he was 4 years old.While Adam has always been a very sweet boy he would exhibit ADHD/Autism like behavior at times. We went to various professionals, with Adam finally receive an ADHD diagnosis in the Spring 2014.
Although Adam began treatment (Adderall XR) for ADHD we still saw persistent irrational fears, asking the same question multiple times, TICs, the list of abnormal behaviors is a long one. Once we moved to Oklahoma we saw the symptoms increasing, especially when he became ill.
We were very fortunate to have found Dr. Daily, she quickly recognized that Adam could possibly have a PANS diagnosis. She began a treatment of antibiotics in late may, with ibuprofen and escitalopram. Yesterday we received the results of Adam's Cunningham panel with Dr. Daily noting that Adam qualifies for the diagnosis of PANS. I would add that as of today Adam is responding very well to the treatment.
I cannot thank you enough for your work in this field. Your work as well as Dr. Daily's diagnostic abilities have changed our lives.
Wendy Elliott, Adam Elliott's mother
p: (405) 239-5250 | f: (405) 239-5255 | 755 Research Parkway, Suite 410, Oklahoma City, OK 73104
Dr. B. Robert Mozayeni was trained in Internal Medicine and Rheumatology at Yale and at NIH. He has had pre- and post-doctoral Fellowships in Molecular Biophysics and Biochemistry at Yale, and also at NIH where he was a Howard Hughes Research Scholar at LMB/DCBD/NCI and later, Senior Staff Fellow at LMMB/NHLBI/NIH. Editorial board of Infectious Diseases – Surveillance, Prevention and Treatment. Past President of the International Lyme and Associated Diseases Society (ILADS).
He is an expert in Translational Medicine, the science and art of advancing medical science safely and efficiently. He is a Fellow of the non-profit Think Lead Innovate Foundation and is a co-founder of the Foundation for the Study of Inflammatory Diseases. He is a Founder of the Foundation for the Study of Inflammatory Diseases to crowd-source medical solutions for complex conditions using existing knowledge, diagnostic methods, and therapies to meet patient needs immediately. He is the Chief Medical Officer of Galaxy Diagnostics, LLC. He is a Board member of the Human-Kind Alliance. Dr. Mozayeni has held admitting privileges (since 1994) on the clinical staff of Suburban Hospital, a member of Johns Hopkins Medicine and an affiliate of the National Institutes of Health Clinical Center.
Safedin Sajo Beqaj, PhD, HCLD, CC (ABB)
Moleculera Labs, Clinical Laboratory Advisor
Medical Database, Inc., President and CEO
Dr. Sajo Beqaj is board certified in molecular pathology and genetics and licensed as a Bioanalyst and High Complexity Laboratory Director. He has been practicing as a laboratory director since 2005.
Dr. Beqaj served as a technical director and was part of the initial management team for several well-known laboratories in the clinical lab industry including PathGroup, Nashville, TN; DCL Medical Laboratories, Indianapolis, IN, and Pathology, Inc, Torrance, CA. He is currently serving as off-side CLIA laboratory director for BioCorp Clinical Laboratory, Whittier, CA and Health360 Labs, Garden Grove, CA.
Dr. Beqaj received his Ph.D. in Pathology from Wayne State University Medical School, Detroit, Michigan. He performed his post-doctoral fellowship at Abbott Laboratories from 2001-2003 and with Children’s Hospital and Northwestern University from 2003-2005.
Dr. Beqaj has taught in several academic institutions and has published numerous medical textbook chapters and journal articles. He has served as a principal investigator in clinical trials for several well-known pharmaceutical and diagnostic companies such as Roche HPV Athena, Merck HPV vaccine, BD vaginitis panel, Roche (Vantana) CINtec® Histology clinical trials, and has presented various scientific clinical abstracts and presentations.
He is a member of several medical and scientific associations including the Association of Molecular Pathology, American Association of Clinical Chemistry and the Pan Am Society for Clinical Virology. He has served on a number of clinical laboratory regulatory and scientific committees, and has assisted several laboratories and physicians as a Clinical Laboratory Consultant.
Rodney Cotton, MBA
Moleculera Labs Board Member
Rodney Cotton, MBA is an entrepreneurial thought leader in the pharmaceutical/biotech industry who is known for his holistic perspective, bias for action in the face of challenges, and commitment to agile processes.
Rod is an independent director for Orchard Software, a private equity-backed health technology company owned by Francisco Partners; an advisory board member to Flo2 Ventures, a venture capital-backed healthcare and health equity accelerator; and a member of the board of directors and three board committees (Audit, Compliance & Finance; Governance & Equity; and Quality of Care) for Community Health Network.
He built a successful career at Roche spanning more than two decades and culminating in the role of SVP, Head of Strategy & Transformation, and Chief of Staff to the CEO for Roche Diagnostics, the North American headquarters of the world’s largest ($17B) diagnostics company.
While at Roche, Rod led key enterprise initiatives, such as milestone corporate communications, health equity coalitions, the US/Roche Group audit, and global/US acquisition integrations. With 40+ years of experience, he drove the financial turnaround and cultural transformation of four global healthcare companies, led teams of up to 280 total reports, managed P&L of more than $1 billion, and served as a key member of the senior leadership team executing the most significant restructuring of the company in two decades.
In the face of the COVID-19 pandemic, Rod and his team at Roche accelerated six ground breaking products in 11 months, including the first launch of the market’s most accurate and in demand molecular diagnostic test. He also solved extraordinary challenges of product scarcity, supply chain, product allocation, and logistics to achieve accelerated global sourcing and self manufacturing in line with testing guidelines.
A frequent public speaker on health equity and other topics, Rod was named one of the Most Influential Black Executives in Corporate America by Savoy Magazine and one of the Top Blacks in Healthcare by BlackDoctor.org. He also received The Sagamore of the Wabash Award, one of the highest Indiana State honors, bestowed by Indiana Governor Eric J. Holcomb.
Rod holds an M.B.A. from California State University, Dominguez Hills, an M.S. in Strategic Management from the University of Southern California, and a B.A. in Biological Sciences & Technology from the University of California at Santa Barbara.